Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Lowered by Maxim Group

Iterum Therapeutics (NASDAQ:ITRM) was downgraded by stock analysts at Maxim Group from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

A number of other analysts have also recently weighed in on ITRM. Wall Street Zen cut Iterum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Iterum Therapeutics in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.00.

Iterum Therapeutics Stock Down 0.7%

NASDAQ ITRM opened at $0.17 on Wednesday. Iterum Therapeutics has a 52 week low of $0.14 and a 52 week high of $1.50. The firm has a 50 day moving average of $0.29 and a two-hundred day moving average of $0.50. The stock has a market capitalization of $8.92 million, a PE ratio of -0.22 and a beta of 2.96.

Institutional Investors Weigh In On Iterum Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of Iterum Therapeutics in the third quarter valued at approximately $32,000. Jane Street Group LLC purchased a new position in Iterum Therapeutics during the 2nd quarter worth $92,000. OneDigital Investment Advisors LLC grew its position in Iterum Therapeutics by 18.6% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock worth $128,000 after purchasing an additional 30,000 shares during the last quarter. Alchemi Wealth LLC acquired a new position in Iterum Therapeutics in the fourth quarter valued at $90,000. Finally, Apollon Financial LLC raised its holdings in shares of Iterum Therapeutics by 151.8% in the fourth quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock valued at $211,000 after buying an additional 380,000 shares during the last quarter. Hedge funds and other institutional investors own 9.21% of the company’s stock.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).